SCHEMBL3930276

SCHEMBL3930276

CCOC(=O)c1ccc(-n2ccc3c(OC4CCN(C(=O)OCC(C)C)CC4)cccc32)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.54
HRH3 Q9Y5N1 1/20 0.39
PDE4B Q07343 1/20 0.38
NPY2R P49146 1/20 0.37
CCR8 P51685 1/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HSD17B10 Q99714 1/20 0.36
PLA2G1B P04054 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493791 0.87 GPR119 (0.71) GPR119PDE4BALDH1A1NPSR1LMNA
SCHEMBL3925483 0.85 GPR119 (0.55) GPR119HRH3
SCHEMBL3927520 0.80 GPR119 (0.58) GPR119HRH3PDE4BNPY2RALDH1A1
SCHEMBL3929833 0.76 GPR119 (0.60) GPR119PDE4B
SCHEMBL3938347 0.75 GPR119 (0.58) GPR119
SCHEMBL3929129 0.72 GPR119 (0.78) GPR119PDE4B
SCHEMBL3928952 0.72 JAK2 (0.46) GPR119ALDH1A1TSHRLMNAKDM4E
SCHEMBL2950876 0.72 MAPT (0.61) ALDH1A1TSHRNPSR1LMNAMAPT
SCHEMBL3935155 0.71 GPR119 (0.76) GPR119PDE4B
SCHEMBL14746764 0.70 SCD (0.48) GPR119SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2043744-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2009-04-08 EP disclosed
WO-2008008895-A1 GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed
WO-2008008887-A2 GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed